Bridging the Clinical Divide with Adult Genetic Services

Integrating adult genetic services into routine reproductive healthcare addresses a persistent gap in modern maternal-fetal medicine. Adult patients with recognized or suspected hereditary disorders frequently encounter fragmented care when planning pregnancy. Consequently, clinicians often struggle to reconcile complex maternal comorbidities with fetal genetic risks. To bridge this critical shortfall, multidisciplinary teams are establishing dedicated adult reproductive genetics clinics. In a recent cohort study, researchers evaluated 112 patients between July 2022 and September 2025 to determine clinical impact. Among these individuals, 53% attended preconception visits, whereas 47% presented during active pregnancy. These comprehensive evaluations allowed clinicians to offer diagnostic testing to 67% of referred individuals. Moreover, 77% of offered patients chose to complete the recommended genetic testing protocols. Historically, adult genetic conditions remained isolated within general genetics or specialty clinics. Today, collaborative care models unite clinical geneticists, maternal-fetal medicine subspecialists, and obstetricians. This integrated framework directly informs reproductive decisions, optimizes maternal safety, and clarifies inheritance risks for future offspring. Furthermore, timely consultations demystify complex genetic concepts for prospective parents, fostering informed shared decision-making.

Diagnostic Yield and New Molecular Findings

Diagnostic genomic investigations deliver remarkable clinical clarity across preconception and antenatal populations. Specifically, in the cohort of 58 patients completing diagnostic evaluation, 35% obtained a definitive diagnostic result. For instance, clinicians identified 10 entirely new molecular diagnoses that prior evaluations had missed. In addition, the team confirmed 10 previously suspected or established clinical diagnoses through molecular testing. Two patients also received medically actionable incidental findings that required distinct clinical surveillance. Importantly, negative evaluations also provided profound clinical utility for families. Although 62% of tested patients received negative findings, 11 of these cases represented highly informative negative results. These informative negative results definitively excluded suspected hereditary conditions, thereby refining clinical risk assessments. Overall, 56.9% of all completed tests directly altered medical management through confirmed diagnoses, incidental detections, or informative exclusions. Consequently, comprehensive molecular diagnostics establish objective prognostic benchmarks, eliminating diagnostic odysseys for affected adults. Thus, these striking numbers demonstrate that modern molecular diagnostics do not merely confirm academic suspicions. Instead, molecular tests empower obstetricians to tailor clinical interventions with exceptional precision and confidence.

Clinical Impact on Fetal and Neonatal Management

Molecular genetic clarification profoundly transforms fetal surveillance and neonatal care pathways. In particular, when clinicians identify a definitive pathogenic variant prenatally, they can anticipate congenital anomalies with greater accuracy. Consequently, obstetric teams adjust ultrasound surveillance intervals and incorporate targeted fetal echocardiography when indicated. Furthermore, prenatal diagnosis allows pediatric subspecialists to formulate immediate postnatal resuscitation protocols well before delivery. For example, neonatologists can prepare targeted enzyme replacement, metabolic stabilizations, or early surgical interventions based on confirmed genetic etiology. Conversely, informative negative results alleviate substantial psychological distress for expectant parents. Because testing excludes key variants, these reassuring exclusions prevent unnecessary invasive diagnostic testing, such as redundant amniocentesis. Additionally, negative results eliminate unwarranted neonatal intensive care unit admissions for asymptomatic infants. Moreover, coordinated perinatal planning minimizes delivery complications by establishing structured delivery parameters at tertiary facilities. Thus, precise molecular insights prevent both overtreatment and missed diagnoses during the vulnerable perinatal period. In this manner, integrated genetics transforms empiric neonatal assumptions into personalized, evidence-based perinatal care.

Maternal Health Implications and Care Coordination

Genetic diagnoses in reproductive-aged adults often carry substantial maternal morbidity that pregnancy can exacerbate. For example, prospective mothers with underlying connective tissue disorders, vascular anomalies, or channelopathies face heightened risks of aortic dissection, severe hemorrhage, or cardiac arrhythmias. Therefore, identifying these pathogenic variants preconceptionally allows multidisciplinary teams to stratify maternal hemodynamic tolerance before conception. As a result, obstetricians and cardiologists can modify pharmacotherapy, replacing teratogenic drugs with safer alternatives. In addition, delivery teams can develop proactive anesthetic plans to minimize maternal stress during labor and delivery. Diagnostic clarity also directs ongoing maternal surveillance beyond pregnancy, ensuring appropriate long-term organ monitoring. Moreover, identifying a monogenic disorder frequently uncovers broader familial implications. Consequently, cascade testing enables first-degree relatives to undergo targeted evaluation, uncovering unsuspected health risks across extended family pedigrees. Furthermore, early identification of systemic maternal pathology ensures vigilant postpartum monitoring during periods of rapid vascular and hemodynamic shifts. Ultimately, adult reproductive genetic evaluation safeguards maternal longevity while simultaneously protecting future generations through proactive familial screening.

Relevance for Obstetric Practice in India

The clinical insights from integrated genetics clinics hold immense relevance for healthcare delivery across India. In fact, non-communicable diseases, congenital anomalies, and rare genetic disorders contribute increasingly to infant morbidity and mortality throughout the country. Furthermore, high rates of endogamy and consanguinity in various communities elevate the baseline risk for autosomal recessive conditions. However, adult patients with genetic conditions frequently experience delayed diagnoses due to limited clinical genetic facilities in primary and secondary healthcare centers. Therefore, integrating adult genetic counseling into tertiary obstetric departments and maternal-fetal medicine units offers a transformative solution. Obstetricians in India can identify at-risk couples preconceptionally, enabling timely preimplantation genetic testing or early chorionic villus sampling. Additionally, national initiatives like the National Policy for Rare Diseases highlight the urgency of expanding genomic infrastructure. By establishing structured interdisciplinary referral protocols, Indian healthcare institutions can democratize access to advanced molecular testing. Ultimately, integrating adult genetic services into pregnancy care will reduce preventable infant mortality and elevate maternal healthcare standards nationwide.

Frequently Asked Questions

When should clinicians refer adult patients for genetic evaluation in pregnancy?

Clinicians should initiate adult genetic evaluation whenever an individual or couple presents with an unexplained personal or familial history of congenital anomalies, intellectual disabilities, cardiomyopathy, or suspected connective tissue disorders. Moreover, preconception referral provides an ideal window to complete genomic testing, discuss recurrence risks, and explore reproductive options such as preimplantation genetic testing. In addition, when patients present during active pregnancy, prompt referral allows tailored fetal surveillance, specialized delivery planning, and timely neonatal interventions.

How do informative negative results influence reproductive management?

An informative negative genetic result occurs when testing definitively excludes a specific familial pathogenic variant or clear syndromic diagnosis in the prospective parent. Consequently, this outcome eliminates the elevated recurrence risk for the offspring, which significantly reduces parental anxiety during gestation. Furthermore, obstetricians can avoid unnecessary high-risk fetal invasive procedures, intensive diagnostic monitoring, or specialized delivery precautions. Therefore, informative negative results actively guide clinical decision-making, reassuring families while optimizing resource allocation across prenatal maternal-fetal services.

What barriers exist when establishing adult genetics in antenatal clinics?

Establishing these specialized services requires overcoming significant barriers, including a shortage of certified clinical geneticists and limited genomic literacy among frontline obstetricians. Additionally, high out-of-pocket costs and variable turnaround times for advanced molecular panels create notable friction for pregnant individuals needing timely answers. Healthcare institutions must therefore establish multidisciplinary referral pathways, train healthcare staff, and integrate genetic counselors within routine antenatal care. Consequently, structured interdisciplinary pathways can streamline equitable access, ensuring actionable genetic guidance reaches vulnerable families.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Dyke MJ et al. The Value of Integrating Adult Genetic Services Into Pregnancy Care: Changing Fetal, Neonatal, and Maternal Management. Am J Med Genet A. 2026 Oct 08. doi: 10.1002/ajmg.a.70329. PMID: 42850202.


2. American College of Obstetricians and Gynecologists. Counseling About Genetic Testing and Communication of Genetic Test Results. ACOG Committee Opinion No. 693. Obstet Gynecol. 2017;129(4):e96-e101.


3. Puri RD, Bijarnia-Mahay S, Preethish-Kumar V, Verma IC. Preconception and Prenatal Genetic Screening: An Indian Perspective. Indian J Pediatr. 2021;88(12):1210-1216.